One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?.
doi : 10.1200/JCO-24-02482
Volume 43(12) pgs. 1401-1522 April 20, 2025
Data, Models, and Visuals: How Data Science Methods Can Augment (Geriatric) Oncology Research.
doi : 10.1200/JCO-25-00053
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival Results.
doi : 10.1200/JCO.24.00933
Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Results From the Prospective BladderPath Trial.
doi : 10.1200/JCO.23.02398
Machine Learning to Predict Mortality in Older Patients With Cancer: Development and External Validation of the Geriatric Cancer Scoring System Using Two Large French Cohorts.
doi : 10.1200/JCO.24.00117
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.
doi : 10.1200/JCO-24-01360
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
doi : 10.1200/JCO-24-02239
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
doi : 10.1200/JCO.24.01174
Postoperative Radiotherapy +/- Cetuximab for Intermediate-Risk Head and Neck Cancer.
doi : 10.1200/JCO-24-01829
Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
doi : 10.1200/JCO-24-02259
Reply to: Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.
doi : 10.1200/JCO-25-00088
Erratum: Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.
doi : 10.1200/JCO-25-00475
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
doi : 10.1200/JCO-25-00466
